IGBA releases first global Intellectual Property and Competition Report (February 2025)
The International Generic and Biosimilar Medicines Association (IGBA) in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines; and of promoting intellectual property regimes which foster innovation and allow the timely entry of generic and biosimilar medicines, has released its report called “GAMING THE SYSTEM- An overview of originator companies’ evergreening strategies used to hinder access to generic and biosimilar products”.